<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04945616</url>
  </required_header>
  <id_info>
    <org_study_id>SHR2285-106</org_study_id>
    <nct_id>NCT04945616</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects</brief_title>
  <official_title>Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR2285 Tablets Combined With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for&#xD;
      SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of&#xD;
      gender. The subjects are divided into three groups: A, B, and C, with 16 cases in each of&#xD;
      groups A and B, and 20 cases in group C.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2021</completion_date>
  <primary_completion_date type="Actual">October 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events and severity of adverse events.</measure>
    <time_frame>from the first dose to 48hours after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Maximum observed serum concentration (Cmax) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite steady state after multiple administrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Time to maximum observed serum concentration (Tmax) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Time to elimination half-life (T1/2) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-last</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC0-last) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax，ss</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Steady-state peak concentration (Cmax，ss) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough，ss</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Steady state valley concentration (Ctrough，ss) for acetylsalicylic acid and its active metabolite salicylic acid, clopidogrel, ticagrelor and its active metabolite AR-C124910XX, SHR2285 and its active metabolite at steady state after multiple administrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FXI activity</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Clotting factor XI (FXI) activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APTT</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Change of activated partial thromboplastin time (APTT) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PT</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Change of prothrombin time (PT) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>from Day1 to Day8 after the first dose</time_frame>
    <description>Change of international normalization ratio (INR) from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>group A： Aspirin + Clopidogrel + placebo or SHR2285 (dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group B ：Aspirin + Clopidogrel + placebo or SHR2285 (dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group C： Aspirin + Ticagrelor + placebo or SHR2285</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin、clopidogrel、placebo or SHR2285</intervention_name>
    <description>groupA： Aspirin + clopidogrel + placebo or SHR2285 (dose 1) ；</description>
    <arm_group_label>group A： Aspirin + Clopidogrel + placebo or SHR2285 (dose 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin、clopidogrel、placebo or SHR2285</intervention_name>
    <description>groupB： Aspirin + clopidogrel + placebo or SHR2285 (dose 2)</description>
    <arm_group_label>group B ：Aspirin + Clopidogrel + placebo or SHR2285 (dose 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin、ticagrelor、placebo or SHR2285</intervention_name>
    <description>groupC： Aspirin + ticagrelor + placebo or SHR2285</description>
    <arm_group_label>group C： Aspirin + Ticagrelor + placebo or SHR2285</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy subjects, aged 18-55 (including boundary);&#xD;
&#xD;
          2. Body mass index (BMI) between 19 to 28 kg/m2 (including boundary), male body weight&#xD;
             ≥50 kg and &lt;90 kg , female body weight ≥45kg and &lt;90kg;&#xD;
&#xD;
          3. Participant with no clinically significant findings in vital signs, physical&#xD;
             examination, 12-lead ECG ,X-ray and laboratory parameters，etc.&#xD;
&#xD;
          4. Understand the study procedures and methods, voluntary to participate in the study and&#xD;
             signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total&#xD;
             bilirubin/direct bilirubin &gt; 1.2 fold ULN during screening/baseline.&#xD;
&#xD;
          2. Serum creatinine&gt; ULN during screening/baseline.&#xD;
&#xD;
          3. Positive faecal occult blood&#xD;
&#xD;
          4. Abnormal coagulation function.&#xD;
&#xD;
          5. A clinical history of coagulation dysfunction; subjects with adverse reaction of&#xD;
             antiplatelet drugs or anticoagulant drugs.&#xD;
&#xD;
          6. Subjects with severe head trauma or head surgery within 2 years or surgery within 3&#xD;
             months prior to the screening.&#xD;
&#xD;
          7. Blood donation or blood loss within 1 month≥200 mLor≥400 mL within 3 months before&#xD;
             administration.&#xD;
&#xD;
          8. Human immunodeficiency virus antibody, syphilis serological examination, hepatitis b&#xD;
             virus surface antigen, hepatitis c virus antibody were positive.&#xD;
&#xD;
          9. 3 months prior to screening involved in any drug or medical device clinical studies. .&#xD;
&#xD;
         10. Female subjects who did not receive contraception at least 30 days before&#xD;
             administration and etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

